Université Paris-Saclay, Laboratoire Européen de Recherche pour la Polyarthrite rhumatoïde - Genhotel, Univ Evry, Evry, France.
Lifeware Group, Inria, Saclay-île de France, Palaiseau, France.
Front Immunol. 2024 Feb 13;14:1282859. doi: 10.3389/fimmu.2023.1282859. eCollection 2023.
The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing.
Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors.
Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19.
The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.
COVID-19 疾病图谱项目是一项大型的社区努力,团结了来自全球 130 个机构的 277 名科学家。我们使用高质量、机械论的内容来描述 SARS-CoV-2 与宿主的相互作用,并开发可互操作的生物信息学管道,用于新的靶点识别和药物再利用。
广泛的社区工作使系统生物学工具和平台之间的接口构建取得了令人瞩目的进展。我们的框架可以将来自组学数据分析和计算建模的生物分子与细胞、组织或患者特异性的失调途径联系起来。使用文本挖掘和 AI 辅助分析的药物再利用方法,确定了可能针对已识别关键因素的潜在药物、化学品和 microRNA。
结果揭示了已经测试过抗 COVID-19 疗效的药物,为其作用机制提供了一个机制背景,以及已经在临床试验中用于治疗其他疾病的药物,从未针对 COVID-19 进行过测试。
关键的进展是,所提出的框架是多功能和可扩展的,为病毒-宿主相互作用和其他复杂病理提供了一个重要的升级。